Top HRT Patch Brands Revolutionizing Hormone Therapy

Hormone Replacement Therapy (HRT) patches have become a vital solution for many individuals seeking relief from menopausal symptoms. These patches provide a convenient and effective way to deliver hormones directly through the skin, helping to balance hormone levels and improve quality of life. With a variety of brands available, choosing the right patch can be a personalized decision based on one's specific needs and preferences. Below, we explore some of the top-rated HRT patch brands, highlighting their features and benefits to help guide your choice.

Illustration of hrt patches

Best brands of hrt patches in 2025

Estradot

Estradot, a prominent brand in the hormone replacement therapy (HRT) market, is renowned for its high-quality transdermal patches. These patches, such as estradiol-only and combination patches, offer consistent hormone delivery and minimized gastrointestinal side effects, making them a preferred choice for postmenopausal women. The market for estradiol transdermal patches is projected to grow at a CAGR of 5.5% from 2024 to 2031, reaching $12.82 billion by 2031, driven by rising healthcare spending and the increasing popularity of HRT.

Climara

Climara, a brand name for estradiol, is a highly effective and widely used transdermal patch for hormone replacement therapy (HRT), particularly for managing menopausal symptoms such as hot flashes and vaginal dryness. Approved by the FDA in 1994, Climara delivers a controlled dose of estradiol over a 7-day period, with various strengths available, including 0.025, 0.05, 0.075, and 0.1 mg per day. Clinical studies have shown that Climara significantly reduces the frequency of hot flashes, with a mean overall decline of 74.6% for the 0.1 mg patch and 64.5% for the 0.05 mg patch. The patch is well-tolerated, with excellent adhesion and minimal skin irritation comparable to other products like Estraderm. However, as of 2024, all doses of Climara have been deleted from the market due to supply issues. For more detailed information, you can refer to the FDA labeling documents for Climara.

Vivelle-Dot

Vivelle-Dot is a leading brand in the production of hormone replacement therapy (HRT) patches, particularly renowned for its effectiveness in managing menopausal symptoms such as hot flashes and vaginal dryness. Approved by the FDA, Vivelle-Dot has established a strong track record since its launch, with over 1.2 million prescriptions in the US in 2020, accounting for around 30% of estradiol patch prescriptions. The patches are available in various dosage strengths, ranging from 0.025 to 0.1 mg/day, and are known for their smaller size and biweekly application, offering greater convenience. Clinical trials have shown that Vivelle-Dot starts alleviating symptoms from the first week of treatment and maintains an acceptable safety profile. Its popularity has seen an upward trend over the last decade due to its low incidence of side effects like skin irritation. For more detailed information, you can visit the official product resource.

Mylan

Mylan, a prominent player in the pharmaceutical industry, is recognized for its high-quality hormone replacement therapy (HRT) patches, which are designed to alleviate symptoms of menopause and other hormonal imbalances. The global HRT market, in which Mylan is a key participant, is projected to grow from $22.5 billion in 2023 to $43.7 billion by 2033, with a CAGR of 6.8%. Mylan's HRT products, including transdermal patches, are favored for their ease of use and effective drug delivery, contributing to the market's expansion. In the transdermal patch market, which is expected to reach $12.5 billion by 2033, Mylan's products are particularly popular in homecare settings, where they hold over 75.8% of the market share. The company's commitment to innovation and patient care has solidified its position as one of the best producers of HRT patches.

Sandoz

Sandoz, a renowned pharmaceutical company, is a leading producer of hormone replacement therapy (HRT) patches, particularly estrogen patches, which have gained significant traction due to their efficacy and safety profile. These patches, such as those delivering 17-beta Estradiol, offer a lower risk of blood clots and heart attacks compared to oral HRT, making them a preferred choice for many women. The market for HRT patches, including those from Sandoz, is projected to grow at a CAGR of 5.5% from 2024 to 2031, reaching a market size of USD 12.82 billion by 2031. The convenience and steady hormone release of these patches minimize fluctuations and provide consistent symptom relief. Sandoz's commitment to innovative formulations and patient-centric care has made their HRT patches a staple in women's health.

Alora

Alora is a prominent brand in the production of hormone replacement therapy (HRT) patches, particularly for menopausal symptoms. These patches deliver 17-beta Estradiol, a bio-identical hormone, directly through the skin, minimizing the risk of blood clots and heart issues associated with oral HRT. Alora patches are applied semiweekly, providing a steady and convenient dose of hormones, and are available in various doses ranging from 0.025mg/day to 0.1mg/day. The transdermal delivery method of Alora patches bypasses the liver, reducing the risk of stroke and other cardiovascular issues, making them a preferred choice for many women. As part of the growing HRT market, which is expected to reach $53.11 billion by 2032, Alora patches contribute to the increasing demand for non-invasive and effective HRT solutions.

Divigel

Divigel, a prominent brand in the hormone replacement therapy (HRT) market, is known for its effective estradiol gel, which is used to treat moderate to severe vasomotor symptoms associated with menopause. In 2023, the FDA approved ANI Pharmaceuticals' abbreviated new drug application for 0.1% estradiol gel, the generic form of Divigel, highlighting its safety and efficacy. Divigel is part of the transdermal segment, which is anticipated to register a significant CAGR during the forecast period due to the introduction of new gel formation therapies. The product is covered under step therapy criteria by health benefit plans, indicating its medical necessity and widespread use. With the global HRT market projected to grow significantly, Divigel remains a key player in the industry.

Minivelle

Minivelle, developed and manufactured by Noven Pharmaceuticals, is a leading brand in hormone replacement therapy (HRT) patches, particularly noted for its smallest available estrogen patch, approximately the size of a dime (1.65cm2). It is indicated for reducing moderate to severe hot flashes and preventing postmenopausal osteoporosis, available in five dosage strengths (0.025, 0.0375, 0.05, 0.075, and 0.10 mg/day). In 2020, Minivelle was prescribed to around 1.5 million women in the US, accounting for about 10% of transdermal HRT prescriptions. The patch delivers estradiol directly through the skin, bypassing first-pass metabolism by the liver, which can reduce side effects compared to oral medications. Minivelle has maintained a steady prevalence over the last decade despite the increasing availability of various treatment options for managing menopause symptoms.

Fem7

Femseven is a notable brand in the hormone replacement therapy (HRT) market, particularly known for its patches that deliver consistent doses of hormones to manage menopause symptoms. However, users have reported issues with the patches' adhesive, leading some to use additional products like Tegaderm dressings to improve adherence. Despite these challenges, Femseven patches are still considered effective, especially when combined with additional measures to enhance their sticking power. The global HRT market, which includes products like Femseven, is projected to grow significantly, with a CAGR of 7.83% from 2024 to 2031, reaching a market size of USD 49.25 billion by 2031. This growth underscores the increasing demand for effective HRT solutions. For more detailed information, you can visit this HRT patches information sheet.

Evorel

Evorel, a brand by Theramex, is renowned for its high-quality HRT patches, which have been in significant demand, leading to a more than 100% increase in manufacturing capacity over the past 18 months to meet the growing needs of menopausal women. Despite this, some strengths of Evorel patches are currently facing shortages due to an unexpected increase in demand. The company has been working diligently to keep up with the rise in prescriptions, which have more than doubled in England over the past five years. By the end of 2019, Theramex had increased its manufacturing to address previous shortages, but current demand continues to pose challenges. The government and healthcare providers are collaborating to ensure a stable supply of these essential products.